This website is for the U.S, for the other countries please refer to this link.
LONGITUDINAL FOLLOW-UP: SUDOSCAN DEMONSTRATED EFFICACY IN RESULTS FOLLOW-UP SUDOSCAN has proven its clinical utility in the follow-up of sudomotor function. In a Finnish study, SUDOSCAN was used to evaluate the effect of physical activity on cardiovascular risk and metabolic diseases. In patients with the highest level of weekly physical activity (as measured with a pedometer),
SUDOSCAN in Oncology : Chemotherapy InduCed Polyneuropathy Two studies evaluating SUDOSCAN Severe drug-induced neurotoxic adverse effects constitute the second most common cause of dose limitation after haematological adverse effects. Chemotherapy Induced Polyneuropathy (CIPN) is commonly associated with platinum analogues, antitubulins (taxane), the proteasome inhibitor bortezomib, and thalidomide. However, it is poorly investigated at an early
EASD 2019 POSTER: DIABETIC FOOT RISK DETECTION A multi-center study (3 hospitals: Bichat, La Pitié Salpêtrière, Bégin) completed in France established the link between the grade of diabetic foot risk and the decrease of Electrochemical Skin Conductance (ESC) measured with SUDOSCAN. A poster has been presented at the European Association for the Study of Diabetes
Identification and Follow-Up of the at Risk Diabetic Foot Impeto Medical will present SUDOSCAN and the role of quantitative sudomotor testing during the 17th annual conference of WoundHSI, Wound Healing: Science & Industry, on 20-21 June 2019 at New York. The diabetic foot is a very costly complication of diabetes both personally and financially. Pathophysiology
Los Angeles, CA – February 14, 2017 — Impeto Medical CEO and Founder Philippe Brunswick is featured on the award-winning, global TV show, Worldwide Business with kathy ireland®. The segment’s topic is the introduction of the company’s innovative, non-invasive SUDOSCAN™ medical device. Impeto Medical is a privately-owned medical device company. The company’s mission is to
Promotional Communication. The medical devices SUDOSCAN is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12
